CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cytosorbents Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cytosorbents Corp
305 COLLEGE ROAD EAST
Phone: (973) 329-8885p:973 329-8885 PRINCETON, NJ  08540  United States Ticker: CTSOCTSO

Business Summary
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its polymer adsorption technology. Its lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR, ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Operating Officer Vincent J.Capponi 65 5/1/2020 7/1/2005
CEO PHILLIP .CHAN
Chief Executive Officer, Director Phillip P.Chan 52 5/1/2020 7/24/2008
7 additional Officers and Directors records available in full report.

Business Names
Business Name
CTSO
CytoSorbents Europe GmbH
CytoSorbents France SAS
6 additional Business Names available in full report.

General Information
Number of Employees: 198 (As of 3/7/2023)
Outstanding Shares: 52,211,599 (As of 12/11/2023)
Shareholders: 11,200
Stock Exchange: NASD
Federal Tax Id: 980373793


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, March 18, 2024